Professor, Psychiatry, UCLA School of Medicine
Psychiatry
Dr. Stephen R. Marder, MD
|
|
Give Review
Stephen R. Marder, MD practices Psychiatry. He researched medicine at University at Buffalo, School of Medicine and Biomedical Sciences. He has 4 awards "America's Top Doctors", "Top Doctors:LA Area", "Top Doctors:Southern California" and "Super Doctor". Doctor Stephen R. Marder, MD is a published doctor and has 98 publications published. The lastest was: 'The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations.' Stephen Marder accepts Medicare payments and is registered with Medicare.gov.
Publications
- The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations.
- A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable Schizophrenia subjects on antipsychotic therapy.
- Ellen stover.
- Efficacy of lurasidone across five symptom dimensions of Schizophrenia: Pooled analysis of short-term, placebo-controlled studies.
- Learning From People With Schizophrenia.
- Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with Schizophrenia on select antipsychotics and with promi...
- Oxytocin-Augmented Social Cognitive Skills Training in Schizophrenia.
- Comorbidity of Severe Psychotic Disorders With Measures of Substance Use.
- Adapting social neuroscience measures for Schizophrenia clinical trials, part 3: Fathoming external validity.
- Adapting social neuroscience measures for Schizophrenia clinical trials, part 2: Trolling the depths of psychometric properties.
- Psychopharmacology of the negative symptoms: Current status and prospects for progress.
- Clinical trials for negative symptoms - Emerging directions and unresolved issues.
- Defining and measuring negative symptoms of Schizophrenia in clinical trials.
- The Reliability and Validity of the MATRICS Functional Assessment Battery.
- Issues and perspectives in designing clinical trials for negative symptoms in Schizophrenia.
- The genomic psychiatry cohort: Partners in discovery.
- Effects of single dose intranasal oxytocin on social cognition in Schizophrenia.
- First and second generation antipsychotics: translating the results from pragmatic trials into clinical practice.
- Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia.
- Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in Schizophrenia.
- Mid-term and long-term efficacy and effectiveness of antipsychotic medications for Schizophrenia: a data-driven, personalized clinical approach.
- Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?
- Population Pharmacokinetic Modeling of Ziprasidone in Patients With Schizophrenia From the CATIE Study.
- Advancing drug discovery for Schizophrenia.
- A brief cognitive assessment tool for Schizophrenia: construction of a tool for clinicians.
- Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI.
- Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in Schizophrenia.
- Efficacy and specificity of Social Cognitive Skills Training for outpatients with psychotic disorders.
- The brief negative symptom scale: psychometric properties.
- A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with Schizophrenia.
- Methodological issues in negative symptom trials.
- Lessons from MATRICS.
- The Cultural Adaptability of Intermediate Measures of Functional Outcome in Schizophrenia.
- Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheim...
- The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?
- Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.
- Report From the Working Group Conference on Multisite Trial Design for Cognitive Remediation in Schizophrenia.
- Population pharmacokinetics of perphenazine in Schizophrenia patients from CATIE: impact of race and smoking.
- A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for Schizophrenia or schizoaffective disorder inadequately treate...
- Psychosocial treatments to promote functional recovery in Schizophrenia.
- The acute efficacy of aripiprazole across the symptom spectrum of Schizophrenia: a pooled post hoc analysis from 5 short-term studies.
- Better pharmacotherapy for Schizophrenia: what does the future hold?
- Treatment of agitation in patients with Schizophrenia.
- It is time to take a stand for medical research and against terrorism targeting medical scientists.
- Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of Schizophrenia.
- Functional co-primary measures for clinical trials in Schizophrenia: results from the MATRICS Psychometric and Standardization Study.
- The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
- The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
- Sex, race, and smoking impact olanzapine exposure.
- Selective corticostriatal dysfunction in Schizophrenia: examination of motor and cognitive skill learning.
- Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
- Chronic restlessness with antipsychotics.
- The Texas Medication Algorithm Project antipsychotic algorithm for Schizophrenia: 2006 update.
- Newer antipsychotics and the differences between clinical experiences and clinical trials. Interview by Norman Sussman, MD.
- Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.
- The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
- New paradigms for treatment development.
- Aripiprazole effects in patients with acute Schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials.
- A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in Schizophrenia.
- Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for Schizophrenia.
- Lessons from each drug trial.
- Switch or stay?
- Initiatives to promote the discovery of drugs to improve cognitive function in severe Mental illness.
- The NIMH-MATRICS consensus statement on negative symptoms.
- Treatment of Schizophrenia negative symptoms: future prospects.
- Drug initiatives to improve cognitive function.
- A review of agitation in Mental illness: treatment guidelines and current therapies.
- Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry.
- The effects of clozapine and risperidone on spatial working memory in Schizophrenia.
- Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with Schizophrenia or schizoaffective disorder.
- Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy.
- Remission in Schizophrenia: proposed criteria and rationale for consensus.
- Approaching a consensus cognitive battery for clinical trials in Schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
- Physical health monitoring of patients with Schizophrenia.
- Panic disorder: psychopathology, medical management and dental implications.
- The Texas Medication Algorithm Project antipsychotic algorithm for Schizophrenia: 2003 update.
- Do clozapine and risperidone affect social competence and problem solving?
- Schizophrenia, IX: Cognition in Schizophrenia--the MATRICS initiative.
- Posttraumatic stress disorder: psychopathology, medical management, and dental implications.
- Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with ...
- Maintenance treatment of Schizophrenia with risperidone or haloperidol: 2-year outcomes.
- Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with Schizophrenia and schizoaffective disorder.
- Right lateral fusiform gyrus dysfunction during facial information processing in Schizophrenia.
- Alcohol abuse and dependence: psychopathology, medical management and dental implications.
- Prefrontal-posterior parietal networks in Schizophrenia: primary dysfunctions and secondary compensations.
- Overview of partial compliance.
- Clinical guidelines: Dosing and switching strategies for long-acting risperidone.
- Olanzapine treatment for patients with Schizophrenia and cocaine abuse.
- The effects of novel antipsychotics on glucose and lipid levels.
- Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning.
- Bipolar I disorder: psychopathology, medical management and dental implications.
- The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone.
- Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with Schizophrenia.
- Clinical predictors of response to clozapine treatment in ambulatory patients with Schizophrenia.
- The psychopathology, medical management and dental implications of Schizophrenia.
- Can clinical practice guide a research agenda?
- The Mount Sinai conference on the pharmacotherapy of Schizophrenia.
Schools
State University of New York At Buffalo
Denver General Hospital
University Of Southern California
Conditions Treated
- Psychosis Due to Mental Illness
- Schizophrenia
Doctors Specialties
- Psychiatry
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:LA Area
- Top Doctors:Southern California
- Super Doctor
Education
-
University of Southern California - LAC+USC Medical Center -
Denver Health Medical Center -
University at Buffalo, School of Medicine and Biomedical Sciences
Hospital
-
Ronald Reagan UCLA Medical Center
Drug Facts
| NPI NUMBER | 1063437762 | |
| NPPES Provider LastName | MARDER | |
| NPPES Provider FirstName | STEPHEN | |
| NPPES Provider ZIPCode | 900950001 | |
| NPPES Provider State | CA | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 120.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1063437762 |
| Last Name Of The Provider | MARDER |
| First Name Of The Provider | STEPHEN |
| View All |
Similar Doctors
|
|
Dr. Brett D. Shurman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Gitlin, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Donna Ames, MD |
|
|
Dr. Elise R. Block, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roderic Gorney, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. James E. Luzano, MD |
|
|
Dr. Kira A. Williams, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alan Markie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nathaniel D. Ginder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melanie S. Midget, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katherine L. Carlson, MD
This Doctor is OpenDoctor Recommended.
|